Table III.
Associated risk analysis between the gastric cancer and the haplotypes constructed by LMP2/LMP7 gene polymorphisms.
| Incidence, n | ||||||
|---|---|---|---|---|---|---|
| Haplotype | Gastric cancer | Control | Crude OR (95% CI) | P-value | Adjusted OR (95% CI)a | P-value |
| LMP2 (Arg)-LMP7 (Gln) | 616 | 659 | 1 | 1 | ||
| LMP2 (Arg)-LMP7 (Lys) | 211 | 165 | 1.37 (1.09–1.72) | 0.008 | 1.34 (1.06–1.70) | 0.013 |
| LMP2 (His)-LMP7 (Gln) | 173 | 178 | 1.04 (0.82–1.32) | 0.746 | 1.04 (0.82–1.32) | 0.751 |
| LMP2 (His)-LMP7 (Lys) | 4 | 2 | 2.14 (0.39–11.72) | 0.381 | 2.13 (0.38–11.86) | 0.387 |
OR, odds ratio; CI, confidence interval; LMP, low molecular weight protein.